Prevalence and risk factors for persistent atrial fibrillation in obstructive sleep apnea

ABSTRACT

Objectives: Obstructive sleep apnea (OSA) is a common cause of atrial fibrillation (AF). The prevalence rate of OSA in AF is highest at 80%. There is limited data if who will develop AF in OSA patients. This study aimed to evaluate the prevalence of AF in patients with OSA and find clinical factors predictive of AF in patients with OSA. Material and Methods: This was a cross-sectional study. We enrolled consecutive patients diagnosed with obstructive sleep apnea diagnosed by polysomnography. The primary outcome was persistent AF identified by electrocardiogram. Prevalence and predictors of AF in patients with OSA were analyzed. Results: During the study period, there were 199 patients with OSA enrolled in the study. Of those, 31 patients (15.57%) had AF. There were five factors in the final model predictive for AF in OSA patients. Among those factors, three factors were independently associated with AF in OSA including age, tiredness, and glomerular filtration rate. The latter two factors were protective factors, while age was a predictor for AF with an adjusted odds ratio (95% confidence interval) of 1.052 (1.004, 1.103). Conclusion: The prevalence of AF in patients with OSA was 15.57%. Elderly patients with renal deterioration are at risk of AF but AF risk was decreasing in patients with tiredness.

Keywords: Prevalence; Age; Glomerular Filtration Rate; Obstructive Sleep Apnea.
INTRODUCTION

Atrial fibrillation (AF) is a common arrhythmia. It is reported that AF is associated with several cardiovascular conditions such as myocardial infarction, heart failure, and stroke1. The presence of AF may increase mortality by two times in patients with myocardial infarction2. There are several causes of AF such as mitral stenosis or obstructive sleep apnea (OSA).

OSA is prevalent and has a rising trend. A survey in the US found that 12-18 million adults may have untreated OSA which is associated with hypertension, stroke, and death3,4. Additionally, OSA is also associated with AF as recommended by the European Society of Cardiology guideline5. In nonvalvular AF, OSA is a common cause with a prevalence rate between 30-85%6-12.

Several mechanisms have been proposed for the association of AF and OSA including intermittent hypoxemia during sleep, intrathoracic pressure shifts, sympathovagal imbalance, or atrial remodeling13. Several studies also showed the risk factors of OSA in patients with AF10,12. The study from Poland found that risk factors of OSA in patients with AF were older (59.6 vs. 56.0 years; \(p<0.02\)), more obese (BMI=30.9 vs. 28.7kg/m²; \(p<0.01\)), and larger neck (41.2 vs. 39.3cm; \(p<0.01\)) than those without OSA11.

On the other hand, there is limited data on prevalence and risk factors of AF in patients with OSA14,15. A study from Germany found the prevalence of AF in OSA patients of 8.9%16. Patients with OSA tended to have older age (63.5 vs. 54.5 years; \(p<0.05\)) and had more proportions of hypertension and coronary artery diseases than those without OSA by unadjusted statistical method. This study aimed to evaluate the prevalence of AF in patients with OSA and find clinical factors predictive of AF in patients with OSA using the adjusted method. Additionally, this study was an additional study to pool up more data on this issue. Physicians may be able to predict AF occurrence in OSA suspected patients without a need for polysomnography.

MATERIAL AND METHODS

This was a cross-sectional study conducted at Khon Kaen University’s obstructive sleep apnea clinic in Thailand. The study period was between September and December 2018. We enrolled all consecutive patients diagnosed with OSA by evidence of an apnea-hypopnea index (AHI) value of five events per hour or more by a polysomnography16. The primary outcome was persistent AF identified by electrocardiogram (ECG). Persistent AF was defined by the persistence of AF by resting electrocardiogram for more than seven days. AF has these three ECG characteristics including: 1) irregular R-R intervals (when atrioventricular conduction is present), 2) absence of distinct repeating P waves, and 3) irregular atrial activity17. Baseline characters, physical signs, and laboratory results of the eligible patients were studied. Risk factors, symptoms, and complications of OSA were also evaluated. For patients with AF, CHA2DS2VASc and HASBLED scores were evaluated to assess the risk of stroke and major bleeding risk from anticoagulants in patients with AF18.

Statistical analysis

Eligible patients were divided by the presence of AF. Baseline and clinical characteristics of OSA patients with and without AF were compared by descriptive statistics. Multivariate logistic regression analysis was used to find factors predictive of AF in OSA. A univariate logistic regression analysis was performed to calculate the crude odds ratio (OR) of each studied factor. Factors with a \(p\)-value of \(<0.20\) of crude odds ratios or clinical importance by previous research studies were put in the multivariate logistic regression analysis. Analytical results were presented as unadjusted/adjusted OR, and 95% confidence intervals. The goodness of fit of the final predictive model was computed by the Hosmer-Lemeshow method. All analyses were executed by STATA software, version 10.1 (College Station, TX, USA).

RESULTS

During the study period, there were 199 OSA patients enrolled in the study. Of those, 31 patients (15.57%) had AF. There were six factors significantly different between AF and non-AF groups (Table 1) including age, sex, comorbid disease (stroke, heart failure, chronic kidney disease), and tiredness symptom. For example, the AF group had a significantly older age than the non-AF group (65 vs. 57 years; \(p<0.022\)) as shown in Table 1. Regarding physical signs and laboratory results, there was no significant difference between both groups (Tables 2 and 3). The AF group and non-AF group had comparable AHI (21 vs. 20 times/hour) as shown in Table 3. The AF group had CHA2DS2VASc and HASBLED score of 3 and 2, respectively.

There were five factors in the final model predictive for AF in patients with OSA (Table 4). Among those factors, three factors were independently associated with AF in patients with OSA including age, tiredness, and glomerular filtration rate. The latter two factors were protective factors, while age was a predictor of AF with an adjusted odds ratio (95% confidence interval) of 1.052 (1.004, 1.103). The Hosmer-Lemeshow chi-square of the predictive model was 9.84 (\(p<0.276\)).

DISCUSSION

The prevalence of atrial fibrillation in OSA patients was 15.57%. Predictors of AF in OSA patients included age, tiredness, and renal function.

As previously reported, increasing age was related to a higher incidence of AF19. The previous study showed that the age group of 85 years or over had an incidence rate of AF of 17.8%, while the AF incidence of the age group of 55-59 years was 0.7%19. In the older age group, predictors of AF were large body sizes which may be an indicator of OSA20. Additionally, OSA also has a higher prevalence in elderly patients with an increasing trend by age21. Therefore, it is not surprising that AF was increasing by age in OSA patients after adjusting for body mass index (Table 4). This finding was similar to the previous
Atrial Fibrillation in OSA

**Table 1.** Baseline characteristics of obstructive sleep apnea (OSA) patients categorized by presence of atrial fibrillation (AF).

| Factors                                      | Non AF  n=168 | AF n=31 | p-value |
|----------------------------------------------|---------------|---------|---------|
| Median (1st-3rd quartile range) age, years   | 57 (46-65)    | 65 (57-71) | 0.022   |
| Male sex, n (%)                             | 109 (64.88)   | 11 (35.48)  | 0.003   |
| Comorbid diseases                           |               |         |         |
| Coronary artery disease                     | 5 (3.40)      | 1 (3.23)   | 0.999   |
| PVC                                          | 2 (1.36)      | 1 (3.23)   | 0.439   |
| COPD                                         | 4 (2.72)      | 2 (6.43)   | 0.286   |
| GERD                                         | 29 (19.73)    | 3 (9.68)   | 0.301   |
| Diabetes mellitus                           | 61 (41.50)    | 14 (45.16) | 0.842   |
| Allergic rhinitis                           | 33 (22.45)    | 7 (22.58)  | 0.999   |
| Chronic kidney disease                      | 45 (30.61)    | 3 (9.68)   | 0.015   |
| Stroke                                       | 8 (5.44)      | 7 (22.58)  | 0.006   |
| Hypertension                                | 119 (80.95)   | 24 (77.42) | 0.626   |
| Heart failure                               | 11 (7.48)     | 9 (29.03)  | 0.002   |
| Hyperthyroidity                              | 3 (8.11)      | 4 (20.00)  | 0.226   |
| Tiredness                                    | 43 (87.76)    | 15 (57.69) | 0.007   |
| Excessive daytime sleepiness                | 68 (64.15)    | 16 (59.26) | 0.660   |
| Previous smoking                            | 22 (22.92)    | 1 (8.33)   | 0.455   |
| Current smoking                             | 6 (6.19)      | 0           | 0.999   |
| Current alcohol                             | 5 (5.75)      | 1 (8.33)   | 0.549   |
| Median (1st-3rd quartile range)             | 5 (4.6)       | 5 (4.5)    | 0.587   |
| STOPBANG, points                            |               |         |         |

**Table 2.** Physical signs of obstructive sleep apnea patients categorized by presence of atrial fibrillation (AF).

| Factors                                      | Non AF  n=168 | AF n=31 | p-value |
|----------------------------------------------|---------------|---------|---------|
| Body mass index, kg/m²                        | 29.3 (26.0-34.4) | 29.0 (24.7-32.5) | 0.322   |
| Systolic blood pressure, mmHg                | 139 (128-150)  | 140 (128-155)  | 0.864   |
| Diastolic blood pressure, mmHg               | 79 (71-85)     | 79 (70-87)     | 0.676   |
| Neck circumference (cm)                      | 41 (39-44)     | 43.5 (41-46.5) | 0.163   |
| Mallampati                                   |               |         | 0.573   |
| Class I                                      | 12 (10.34)     | 3 (20.00)    |         |
| Class II                                     | 39 (33.62)     | 42 (26.67)   |         |
| Class III                                    | 48 (41.38)     | 5 (33.33)    |         |
| Class IV                                     | 17 (14.66)     | 3 (20.00)    |         |
| Trousus palatin                              | 13 (9.03)      | 2 (18.18)    | 0.288   |
| Trousus mandibularis                         | 7 (4.90)       | 0           | 0.999   |
| Tonsil enlargement                           | 64 (38.10)     | 8 (25.81)    | 0.226   |
| Microtrigoneathy                             | 4 (2.74)       | 0           | 0.999   |
| Macroglossia                                 | 47 (31.54)     | 4 (33.33)    | 0.999   |
| Retrorglossia                                | 12 (8.39)      | 0           | 0.999   |

**Table 3.** Laboratory results of obstructive sleep apnea patients categorized by presence of atrial fibrillation (AF).

| Factors                                      | Non AF  n=168 | AF n=31 | p-value |
|----------------------------------------------|---------------|---------|---------|
| Apnea hypopnea index (events/hr)             | 21 (11-42)    | 20 (12-28)  | 0.499   |
| Fasting plasma glucose (mg/dL)               | 111 (95-131)  | 99 (96-116) | 0.513   |
| HbA1C (%)                                    | 6.2 (5.6-7.8) | 6.3 (5.7-6.9) | 0.884   |
| Blood urea nitrogen (mg/dL)                  | 14.8 (11.9-21.1) | 17 (12.6-24.2) | 0.300   |
| Creatinine (mg/dL)                           | 1.1 (0.8-1.4) | 1.1 (0.8-1.3) | 0.978   |
| Glomerular filtration rate (ml/min)          | 73 (47-98)    | 65 (49-84)  | 0.131   |
| Uric (mg/dL)                                 | 6.6 (5.4-7.6) | 6.5 (5.3-9.4) | 0.829   |
| Albumin (g/dL)                               | 3.7 (3.4-4.1) | 3.7 (3.4-4.1) | 0.092   |
| Cholesterol (mg/dL)                          | 195 (160-221) | 181 (140-220) | 0.128   |
| Triglyceride(mg/dL)                          | 150 (96-192)  | 128 (97-162) | 0.633   |
| High-density lipoproteins (mg/dL)            | 48 (41-58)    | 49.5 (38.5- 58.5) | 0.933   |
| Low-density lipoproteins (mg/dL)             | 127 (95-159)  | 110 (85-159) | 0.313   |

**Table 4.** Factors associated with occurrence of atrial fibrillation in obstructive sleep apnea patients.

| Factors                                      | Unadjusted odds ratio (95% confidence interval) | Adjusted odds ratio (95% confidence interval) |
|----------------------------------------------|-------------------------------------------------|-----------------------------------------------|
| Age, years                                   | 1.028 (0.999, 1.058)                            | 1.052 (1.004, 1.103)                           |
| Tiredness                                    | 0.190 (0.059, 0.604)                            | 0.155 (0.032, 0.749)                           |
| Glomerular filtration rate                   | 0.992 (0.979, 1.004)                            | 0.967 (0.939, 0.996)                           |
| Body mass index                              | 0.952 (0.891, 1.017)                            | 1.026 (0.899, 1.169)                           |
| Daytime sleepiness                           | 0.812 (0.342, 1.929)                            | 0.444 (0.118, 1.665)                           |

Notes: Data presented as median (1st-3rd quartile range) or number (percentage).

4.65; 95%CI = 1.47, 14.70) by a study from Japan22. Therefore, increasing the glomerular filtration rate may reduce the risk of AF in OSA by 4% per 1ml/min/1.73m² (Table 4).

Tiredness is one symptom listed in the STOP BANG questionnaire for OSA screening23. This symptom was very common and had a higher proportion than loud snoring in the STOP BANG questionnaire (48.0% vs. 41.8%)24. A previous study found that hypertension duration was a predictor of AF in obese OSA patients (adjusted odds ratio 1.10; 95%CI = 1.04, 1.16)25. These data may indicate that a longer duration of OSA is associated with an increasing risk of AF. As tiredness is the common symptom, OSA patients with tiredness may seek medical attention faster than those without tiredness resulting in a lower risk of repeated hypoxemia and AF occurrence (Table 4). In children with OSA, tiredness is also a common leading symptom (64%) presenting to the physicians26. Even though this study found that tiredness is negatively related to AF occurrence in patients with OSA, further studies are required to confirm the results of this study as well as the plausible mechanism of this association.

A recent review found that body mass index may be related to AF27. AF was contributed by body mass index in 17.9% of patients with AF. Additionally, obesity increases the risk of AF by 2.04 times27. A study from Nepal found that

study from Germany even after adjusting for other variables in this study (Table 4)22.

Renal dysfunction had a higher prevalence of OSA and also a predictor of OSA in the elderly with an adjusted odds ratio of 2.32 (95%CI = 1.63, 3.31)22. Chronic kidney disease was reported to be a risk factor for new-onset AF (hazard ratio

Sleep Sci. 2022;15(4):448-452
the rate of AF in patients with OSA was higher if body mass index of over 23.5kg/m² compared to those with lower body mass index (6/7 vs. 1/7 patients)\(^\text{15}\). However, this study did not find a significant correlation between body mass index and AF in patients with OSA (Table 4). There are two possible explanations for these findings. First, our analysis was adjusted for other variables which are more robust and controlled for confounding factors. In other words, body mass index was not a strong predictor compared with other variables. Second, this study was conducted in the Asian population which obesity may be accounted for only 36.6% of patients with OSA\(^\text{29}\).

There are some limitations to this study. First, it was conducted in a single study site in a university hospital setting. Other aspects of OSA or other cardiovascular risk factors were not determined\(^\text{29-32}\). Second, there is no intervention in this study such as continuous positive airway pressure (CPAP) machine therapy\(^\text{33-35}\). Further studies are encouraged to evaluate the effects of CPAP therapy and AF reduction in OSA patients. Finally, further studies may be required to evaluate thromboembolism events in this setting. A previous study found that untreated OSA patients may have a poor response on catheter ablation of AF with a higher rate of recurrence\(^\text{1}\).

**CONCLUSION**

The prevalence of persistent AF in OSA was 15.57%. Elderly patients with renal deterioration increased the risk of AF but AF risk was decreasing in patients with tiredness.

**Ethical consideration**

In order to comply with ethical considerations, the subjects were assured that the information obtained will be only used for research purposes and their profile will be kept confidential during the research and thereafter. An informed consent was not required due to retrospective data collection. The study was approved by the institutional review board (HE541373).

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**Funding/support**

The authors did not use any fund from a commercial party related directly or indirectly to the subject of this article.

**REFERENCES**

1. Shanha G, Pelloi F, Morady F. Relationship between obstructive sleep apnoea and AF. Arrhythmia Electrophysiol Rev. 2019 Jul;8(3):180-3.
2. Raddos V, Sandven I, Munkhaugen J, Skattetu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017 Sep;24(14):1555-66.
3. Soontornrungsun B, Khamsai S, Sawunyavisuth B, Limpawattana P, Chindaprasit J, Senthong V, et al. Obstructive sleep apnea in patients with diabetes less than 40 years of age. Diabetes Metab Syndr. 2020 Nov;14(6):1859-63.
4. Khamsai S, Mahawarokorn P, Limpawattana P, Chindaprasit J, Sukkeepsarnjaroen W, Silaruks S, et al. Prevalence and factors correlated with hypertension secondary from obstructive sleep apnea. Multidiscip Respir Med. 2021 Jan;16(1):777.
5. Khamsai S, Kachnehari S, Sawunyavisuth B, Limpawattana P, Chindaprasit J, Senthong V, et al. Prevalence and risk factors of obstructive sleep apnea in hypertensive emergency. J Emerg Trauma Shock. 2021 Jun;14(2):104-7.
6. Sanlung T, Sawunyavisuth K, Silaruks S, Chattakul P, Limpawattana P, Chindaprasit J, et al. Clinical characteristics and complications of obstructive sleep apnea in Sirirajah hospital. J Med Assoc Thai. 2020;103(1):36-9.
7. Khamsai S, Choostrakool A, Limpawattana P, Chindaprasit J, Sukkeepsarnjaroen W, Chomtongvlool V, et al. Hypertensive crisis in patients with obstructive sleep apnea-induced hypertension. BMC Cardiovasc Disord. 2021 Jun;21(1):310.
8. Kirehho P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Electrophysiol Europ Soc Cardiol. 2016 Nov;18(11):1609-78.
9. Braga B, Poyares D, Cintra F, Guilmantault C, Cirena Z, Horbach S, et al. Sleep-disordered breathing and chronic atrial fibrillation. Sleep Med. 2009 Feb;10(2):212-6.
10. Abumunmar AM, Dorian P, Newman D, Shapiro CM. The prevalence of obstructive sleep apnea in patients with atrial fibrillation. Clin Cardiol. 2018 May;41(5):601-7.
11. Szymanski FM, Planeck AE, Karpirsitk G, Kozluk E, Puchalski B, Filipiak KJ. Obstructive sleep apnoea in patients with atrial fibrillation: prevalence, determinants and clinical characteristics of patients in Polish population. Kardiol Pol. 2014 Mar;72(2):716-24.
12. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004 Nov;110(4):364-7.
13. Khamsai S, Soontornrungsun B, Khamsai S, Sawunyavisuth B, Limpawattana P, Chindaprasit J, et al. Obstructive sleep apnea and AF with a higher rate of recurrence. Eur J Prev Cardiol. 2017 Mar;24:293-300.
14. Erdogan A, Parahuleva M, Schaefer S, Guettler N, Neuhof C, Alcaay B, et al. Prevalence of atrial fibrillation in obstructive sleep apnea. Somnologie. 2009 Nov;13(4):211. DOI: https://doi.org/10.1007/s11818-009-0444-2
15. Dhalak SS, Neupane A, Bhattarai M, Karki DB. Prevalence of atrial fibrillation in obstructive sleep apnea patients in a tertiary care center. J Nepal Med Assoc. 2020 Feb;58(222):80-3.
16. Hendrix T, Sundqvist M, Sandström H, Sahlin C, Rohani M, Al-Khalifi F, et al. Atrial fibrillation among patients under investigation for suspected obstructive sleep apnea. PLoS One. 2017;12(2):e0171575.
17. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec;130(23):2071-104.
18. Lip GYH. Implications of the CRAH(2)DS(2)-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011 Feb;124(2):111-4.
19. Heeringa J, Van der Kuip DAM, Hofman A, Kors JA, Van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006 Apr;27(7):49-53.
20. Berge T, Lyngbakken MN, Ihle-Hansen H, Brynildsen J, Pervez MO, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006 Apr;27(7):49-53.
21. Kodani E, Kaneko T, Fujii H, Nakamura H, Sasabe H, Tamura Y, et al. Impact of chronic kidney disease classification on new-onset atrial fibrillation in the general population - the TAMA MED Project-AF and CKD. Kardiol Pol. 2014 Mar;72(2):716-24.
22. Chung F, Abdullah HR, Liao P. STOP-Bang questionnaire: a tool for thromboprophylaxis in atrial fibrillation. Am J Med. 2011 Feb;124(2):111-4.
23. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2014 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2014 Nov;35(34):2876-914.
24. Lonia L, Scalese M, Rossato G, Bruno G, Zalunardo F, Stefani A, et al. Validity of the STOP-Bang questionnaire in identifying OSA in a dental practice setting. Sleep Sci. 2022;15(4):448-452
Atrial Fibrillation in OSA

25. Korostovtseva LS, Zvartau NE, Rotar OP, Sviryaev YV, Konradi AO. Predictors of heart rhythm disturbances in hypertensive obese patients with obstructive sleep apnea. J Geriatr Cardiol. 2017 Sep;14(9):553-62.

26. Liu AL, Zheng YJ, Su Z, Wei JR, Yang Q, Wang CC, et al. Clinical features of obstructive sleep apnea in children with obesity. Zhongguo Dang Dai Er Ke Za Zhi. 2021 Sep;23(9):933-7.

27. Vyas V, Lambiase P. Obesity and atrial fibrillation: epidemiology, pathophysiology and novel therapeutic opportunities. Arrhythmia Electrophysiol Rev. 2019 Mar;8(1):28-36.

28. Chirakalwasan N, Teerarattanapraip B, Simon R, Hirunwiwatkul P, Jaimchariyatam N, Desudech T, et al. Comparison of polysomnographic and clinical presentations and predictors for cardiovascular-related diseases between non-obese and obese obstructive sleep apnea among Asians. J Clin Sleep Med. 2013 Jun;9(6):553-7.

29. Manasirisuk P, Chainirun N, Tiamkao S, Lertsinudom S, Phunikhom K, Sawunyavisuth B, et al. Efficacy of generic atorvastatin in a real-world setting. Clin Pharmacol. 2021 Mar;13:45-51.

30. Jeerasuwannakul B, Sawunyavisuth B, Khamsai S, Sawanyawisuth K. Association of body mass index and other factors with metabolically unhealthy status: Results from the national health examination survey IV. Asia-Pac J Sci Technol [Internet]. 2021 Jun;[cited 2021 Aug 28];26(02):APST-26-02-09. Available from: https://so01.tci-thaijo.org/index.php/APST/article/view/244135

31. Sawunyavisuth B. What personal experiences of CPAP use affect CPAP adherence and duration of CPAP use in OSA patients? J Med Assoc Thai. 2018;101(7):245-9.